DRAKON
Device
GUERBET LLC
Total Payments
$72,399
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $72,399 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $72,399 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Chemoembolization of Uveal Melanoma Hepatic Metastases using 300mg of BCNU Dissolved in Lipiodol followed by Gelfoam Embolization | GUERBET LLC | $72,399 | 0 |
Top Doctors Receiving Payments for DRAKON
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $72,399 | 1 |
Ad
Manufacturing Companies
- GUERBET LLC $72,399
Product Information
- Type Device
- Total Payments $72,399
- Total Doctors 0
- Transactions 1
About DRAKON
DRAKON is a device associated with $72,399 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is GUERBET LLC.
Payment data is available from 2021 to 2021. In 2021, $72,399 was paid across 1 transactions to 0 doctors.
The most common payment nature for DRAKON is "Unspecified" ($72,399, 100.0% of total).
DRAKON is associated with 1 research study, including "Chemoembolization of Uveal Melanoma Hepatic Metastases using 300mg of BCNU Dissolved in Lipiodol followed by Gelfoam Embolization" ($72,399).